11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
March 2018 in “Trends in Immunotherapy” Combining triamcinolone acetonide with immunotherapy can help regrow hair in some alopecia totalis patients.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
September 2025 in “JAAD International” Thrice-weekly dutasteride improved hair density and thickness more than twice-weekly, but not hair count compared to daily finasteride.
47 citations
,
April 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
30 citations
,
August 2010 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
2 citations
,
November 2020 in “Der Hautarzt” A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
Hair regrowth improved, but quality of life did not.
September 2025 in “Reactions Weekly”
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The combination of oral finasteride and dutasteride with topical minoxidil effectively promotes new hair growth in most people, with minimal side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
57 citations
,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
July 2025 in “International Journal of Trichology” Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
3 citations
,
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The DNN-DTIs method accurately predicts drug-target interactions and is useful for drug repositioning.
July 2025 in “Journal of Investigative Dermatology” July 2022 in “British Journal of Dermatology”